Understanding the science, impact, and prevention strategies for surgical site infections in obstetrics and gynecology
Imagine undergoing a life-changing surgery, only to be readmitted days later with a painful, red, and swollen incision. This is the reality for millions of women worldwide who develop surgical site infections (SSIs) following obstetric and gynecologic procedures. These infections are not merely inconveniences; they represent a significant burden on healthcare systems, particularly in rural tertiary care hospitals where resources are often limited.
In obstetrics and gynecology, the risk of infection is heightened due to the anatomical proximity to naturally colonized areas like the vagina and perineum 2 .
Cesarean sections account for over 40% of deliveries in some regions and are classified as clean-contaminated surgeries 7 .
Surgical site infections are defined as infections occurring at or near the surgical incision within 30 days of surgery (or up to one year if an implant is involved). The CDC classifies them into three distinct categories 5 :
Pregnancy alters immune function, making women more susceptible to certain infections.
The vaginal environment hosts a diverse bacterial community, which can serve as a source of pathogens.
Excess adipose tissue has poor blood perfusion, reducing oxygen delivery and antibiotic penetration. Can increase SSI risk by up to three times 5 .
Perioperative hyperglycemia impairs immune function and increases infection risk 5 .
Hypoalbuminemia indicates malnutrition and is linked to impaired wound healing .
Carries significantly higher risk due to less time for patient optimization. One study found a 100% culture-positive rate in emergency surgeries 3 .
Procedures exceeding 60 minutes are associated with a 2.58-fold increased risk of SSI 7 .
Blood loss exceeding 300 mL is an independent risk factor (OR = 2.54) 7 .
| Risk Factor Category | Specific Factor | Impact on SSI Risk |
|---|---|---|
| Patient-Related | Obesity (BMI ≥24) | 2.66-fold increase 7 |
| Diabetes & Perioperative Hyperglycemia | 1.4-9-fold increase | |
| Procedure-Related | Emergency Surgery | 100% culture positivity vs. 40% elective 3 |
| Operation Time ≥60 min | 2.58-fold increase 7 | |
| Blood Loss ≥300 mL | 2.54-fold increase 7 |
A prospective study conducted at a rural tertiary care hospital followed 100 patients who underwent clean or clean-contaminated surgeries 6 :
| Age Group (Years) | Number of Patients | Number Infected | Infection Rate (%) |
|---|---|---|---|
| ≤50 | 60 | 2 | 3.33% |
| 51-60 | 10 | 1 | 10.00% |
| 61-70 | 10 | 1 | 10.00% |
| ≥71 | 7 | 1 | 14.28% |
| Total | 87 | 5 | 5.75% |
Note: Total patients in this breakdown were 87; overall study included 100 patients. 6
SSIs are responsible for 38% of surgery-related patient deaths. Patients with SSIs are 60% more likely to require ICU care, five times more likely to be readmitted, and twice as likely to die .
SSIs increase healthcare costs due to prolonged hospital stays. In the US, hospital stays are extended by an average of 9.7 days, with an average cost increase of $20,842 per hospital stay 5 .
Infections lead to lost time from work, extended recovery periods, and significant mental anguish for patients and their families.
The high preventability of SSIs (40-60%) has led to the development of evidence-based "care bundles"—sets of interventions performed together to achieve better outcomes 5 .
| Phase of Care | Intervention | Key Details | Rationale |
|---|---|---|---|
| Preoperative | Glycemic Control | Target blood glucose <180 mg/dL | Hyperglycemia impairs immune function |
| Preoperative | Antibiotic Prophylaxis | Cefazolin 2g (3g if ≥120 kg) within 30 min of incision | Targets common skin and vaginal flora |
| Intraoperative | Alcohol-Chlorhexidine Skin Prep | Prep for 30 sec (dry) to 2 min (moist); allow to dry | Rapid and persistent antimicrobial action |
| Intraoperative | Normothermia | Maintain core temp ≥36°C | Prevents vasoconstriction and tissue hypoxia |
| Postoperative | Early Catheter Removal | Remove within 12-24 hours postop | Reduces risk of UTI and ascending infection |
Understanding how SSIs are studied helps appreciate the science behind the recommendations. Here are essential tools used in research:
| Reagent/Material | Primary Function | Application in SSI Research |
|---|---|---|
| Blood Agar Plate | Cultivation of a wide range of bacteria | Primary culture for wound swabs to isolate pathogens 3 |
| MacConkey Agar Plate | Selective cultivation of Gram-negative bacteria | Differentiation of enteric bacteria like E. coli and Klebsiella 3 6 |
| Chromogenic Agar | Selective identification of specific pathogens | Rapid identification of species like Candida, MRSA, and VRE 3 |
| VITEK-2 System | Automated microbial identification & susceptibility testing | Provides accurate ID and antibiotic sensitivity profiles |
| Chlorhexidine Gluconate (2-4%) | Topical antiseptic | Used in preoperative skin preparation for its persistent effect 5 |
Surgical site infections remain a formidable challenge in obstetrics and gynecology, particularly in rural settings where resources are stretched. However, they are not inevitable.
Through a combination of evidence-based practices, patient optimization, and multidisciplinary collaboration, significant progress can be made. The implementation of care bundles—systematic approaches to prevention—has shown remarkable success in reducing infection rates.
The fight against SSIs requires constant vigilance, adaptation, and a commitment to learning from both global research and local studies. By understanding the risk factors, microbiological patterns, and prevention strategies detailed here, healthcare providers in rural tertiary care hospitals can better protect their patients, ensuring that the joy of a new birth or the relief from a gynecologic ailment is not overshadowed by the preventable scourge of infection.